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Tbjective: The Thoratec Implantable Ventricular Assist Device (Thoratec Corpo-
ation, Pleasanton, Calif) can be used for univentricular or biventricular support in
atients with a body surface area as low as 1.3 m2. Results of the multicenter clinical
rial are reviewed.
ethods: Between October 2001 and June 2004, a total of 39 patients at 12
nstitutions were supported with the Thoratec Implantable Ventricular Assist De-
ice. Twenty-four patients (62%) received left ventricular assist devices and 15
38%) received biventricular assist devices. Indications included bridge to trans-
lantation (n  30) and postcardiotomy failure (n  9). The control group included
00 patients from the Food and Drug Administration approval submissions for the
aracorporeal version of the ventricular assist device.
esults: Twenty-eight male and 11 female patients, with mean age of 48 years
16–71 years) and body surface area of 1.9 m2 (1.3–2.4 m2) were supported for 3938
atient-days (10.8 patient-years). Mean left ventricular assist device flow index on
he first postoperative day was 2.5  0.5 L/(min · m2). Mean duration of support
as 101 days (9–597 days). Eighteen patients were discharged after a mean
uration of 96 days. There were no ventricular assist device failures. Complications
ncluded 13 cases of bleeding requiring reexploration (33.3%), 1 embolic and 2
emorrhagic strokes (7.7%), 5 driveline infections (12.8%), and 2 pocket infec-
ions (5%). Support to successful outcomes was 70% for bridge to transplantation
nd 67% for postcardiotomy recovery, versus historical results for the paracorporeal
entricular assist device of 69% for bridge to transplantation and 48% for postcar-
iotomy recovery.
onclusion: The Thoratec Implantable Ventricular Assist Device is a new implant-
ble pulsatile ventricular assist device that allows hospital discharge for patients as
bridge to transplantation or for postcardiotomy failure. It is the first Food and Drug
dministration–approved implantable ventricular assist device with biventricular
apability.
onsiderable progress has been made during the last decades in the devel-
opment of ventricular assist devices (VADs). Initially, failure to wean from
cardiopulmonary bypass was the primary indication for VAD support.1-5
he roles of VADs and artificial hearts have expanded, however, to encompass
upport of patients awaiting cardiac transplantation5-13 and destination therapy as an
lternative to optimal medical management.14-16
The Thoratec Paracorporeal Ventricular Assist Device (PVAD; Thoratec Corpo-
ation, Pleasanton, Calif) is the mainstay of many mechanical circulatory support
rograms. Based on designs that date back to the 1970s,17 it was approved by the
ood and Drug Administration (FDA) in 1995 for bridge to transplantation (BTT)
he Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 6 1573
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1
CSPnd in 1998 for postcardiotomy myocardial recovery. As of
an 2006, more than 3000 patients have been supported for
oth indications with the Thoratec PVAD. Although im-
lantable electric left ventricular assist device (LVAD) sys-
ems are often selected for their wearable controllers and
atteries, the PVAD’s simplicity, size, and biventricular
apability make it the device of choice for many patients. As
ore patients have been supported with the PVAD for
onger durations (longest: 3.3 years of biventricular support
ithout changing pumps), however, a need has arisen for an
mplantable version to facilitate patient discharge from the
ospital and potentially improve quality of life. In addition,
ecause implantable electric LVAD systems have been de-
igned solely for left ventricular support, there is a clinical
eed for implantable assist device options for patients with
evere biventricular failure. The Thoratec Implantable Ven-
ricular Assist Device (IVAD; Thoratec Corporation) was
herefore developed, retaining as much in common with the
VAD system as possible. The system underwent a formal
linical trial and was FDA approved in 2004 on the basis of
he results. This report provides the results of this clinical
rial relative to a historical control group of patients with the
horatec PVAD.
aterials and Methods
evice
he Thoratec IVAD blood pump (Figure 1) was designed with
ncremental changes to the commercially available PVAD, facili-
ating implantation of the pump while retaining the basic flow path
nd pumping mechanisms.18,19 The pump housing material was
hanged from polysulfone and stainless steel to a titanium alloy,
nd the Hall effect pump-full sensor was replaced with an infrared
ensor to detect both pump full and pump empty. The cannulas
ere shortened and the driveline lengthened for implantability.
o changes were made to the blood path geometry in the pump,
nd with the exception of the valve housings (changed from
tainless steel to titanium alloy), the blood contacting materials
re identical.
The Thoratec IVAD was designed for preperitoneal placement
nd is pneumatically powered by an external portable TLC-II
river. A single percutaneous lead for each VAD is used for
Abbreviations and Acronyms
BTT  bridge to transplantation
FDA  Food and Drug Administration
IVAD  implantable ventricular assist device
LVAD  left ventricular assist device
LVAS  left ventricular assist system
NYHA New York Heart Association
PVAD  paracorporeal ventricular assist device
RVAD right ventricular assist device
VAD  ventricular assist deviceneumatic actuation and the sensor wires. Univentricular or biven- i
574 The Journal of Thoracic and Cardiovascular Surgery ● Junricular support (Figure E1, A and B) is possible by using the
ppropriate atrial or ventricular inflow cannula and arterial outflow
annula. The IVAD, which weighs 339 g and has a displaced
olume of 252 mL, is slightly smaller and lighter than the PVAD
weight 419 g, volume 318 mL) and can generate pulsatile flow up
o 7.2 L/min.
ethods
he Thoratec IVAD was studied in a prospective, multicenter,
onrandomized clinical trial for use as a BTT or for patients in
ostcardiotomy recovery who cannot be weaned from cardiopul-
onary bypass. A total of 39 patients were enrolled at 9 centers in
he United States and 3 in Europe. The primary study objective
as to evaluate the safety and effectiveness of the IVAD, as
emonstrated by VAD flow index, survival, and adverse event
ates, and to establish basic equivalence with the PVAD. Survival
esults and adverse events were compared with those among 100
atients in the original clinical trial of the PVAD for BTT and for
ostcardiotomy myocardial recovery.20
Eligible patients were 12 to 70 years of age with acute or
hronic heart failure necessitating VAD support to achieve ade-
uate flow. Study inclusion criteria were similar to current indi-
ations for BTT or postcardiotomy failure and were met before
atient enrollment (Appendix E1). Patients were excluded for any
f the following reasons: active systemic infection, hemodialysis
r hemofiltration requirements, intolerance to anticoagulation or
ntiplatelet therapy, chronic liver disease, elevated serum creati-
ine (4 mg/dL) or total bilirubin (3 mg/dL), recent pulmonary
mbolus, severe cerebrovascular disease, cardiopulmonary resus-
itation on the way to the operating room, and concurrent mechan-
igure 1. Implantable ventricular assist device has same internal
ow path as paracorporeal ventricular assist device, but plastic
ousing is replaced with smooth, contoured, polished titanium
ousing for improved implantability, and driveline is extended
nd covered with polyester velour as percutaneous lead.cal support with any other circulatory support devices.
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CS
PAdverse event definitions used were in compliance with FDA
equirements at the time of the initiation of the clinical trial.
ecause the original PVAD trial used adverse event definitions
ifferent from those used in the IVAD trial, the original PVAD
ata were reviewed and reclassified according to the definitions of
he IVAD trial.
The study was carried out under the regulations for investiga-
ional device exemption of the FDA. Informed consent was ob-
ained before study participation. Each study site obtained institu-
ional review board or ethics committee approval before study
nitiation, and any country-specific approval was obtained before
atient enrollment.
urgical Implantation
he Thoratec IVAD was implanted through a standard median
ternotomy approach. The pocket for the IVAD was developed
elow the left rectus muscle or between the left posterior rectus
ascia and the peritoneum. The driveline was tunneled below the
mbilicus and brought out the right midquadrant above the belt
ine. After heparinization, standard cardiopulmonary bypass was
nstituted. Generally, the inflow and outflow cannulas were in-
erted during cardiopulmonary bypass, with the heart decom-
ressed and beating. Aortic crossclamping was not necessary, and
eft ventricular vents were used at the surgeon’s discretion. The
4-mm outflow graft was sewn to the ascending aorta on the
reater curvature as an end-to-side anastomosis. Left ventricular
pex cannulation was achieved in all patients with LVAD support.
t was possible to cannulate the left atrium through the left atrial
ppendage or the right superior pulmonary vein with the atrial
annula for LVAD support. When a right ventricular assist device
RVAD) was necessary, the outflow graft was sewn as an end-to-
ide anastomosis to the pulmonary artery and the inflow cannula
as inserted either into the right atrium or directly into the right
entricle. After connection of the inflow and outflow grafts to the
ump, the patient was weaned from cardiopulmonary bypass and
he heparin was fully reversed with protamine.
Patients were typically anticoagulated initially with heparin
or the first or second postoperative day at a dosage of about
0 g/(kg · min), gradually increasing to maintain a partial
hromboplastin time of about 1.5 times control. Patients were
witched to warfarin when able to tolerate oral medications at
oses to keep the international normalized ratio at 2.5 to 3.5.
extran, aspirin and dipyridamole were also used in some patients.
Statistical comparisons between groups were conducted with
isher exact test for 2  2 categorical variables and an unpaired t
est for continuous variables.
esults
aseline Demographics
total of 39 patients were enrolled between October 2001
nd June 2004. The baseline demographics were similar for
he IVAD and PVAD cohorts (Table 1). The 28 men and 11
omen ranged in age from 16 to 71 years (mean 48 years),
ad an average body surface area of 1.9 m2 (1.3–2.4 m2),
nd an average weight of 75 kg (42–115 kg). Cardiac
isease etiologies were ischemic (n 13), idiopathic dilated
ardiomyopathy (n  18), other cardiomyopathy (n  1 i
The Journal of Thoracicach for familial, viral, cocaine-induced, chemotherapy in-
uced, and hypertrophic), myocarditis (n  1), and unspec-
fied (n  2). Before implantation, 35 (90%) of the 39
atients were in New York Heart Association (NYHA)
unctional class IV, and all 39 patients had severely
ompromised hemodynamics (Table 1). Twenty-six
atients had a history of arrhythmias, 8 had previous
ardiac arrests, and 23 had previous cardiac surgery,
utomatic implantable cardioverter defibrillators, or
iventricular pacers.
Indications for IVAD use were advanced heart failure
equiring circulatory support as a BTT (n  30) or postcar-
iotomy ventricular failure (n  9) (Table 2). Concomitant
rocedures for the 9 postcardiotomy patients included cor-
nary artery bypass grafting (n  3), mitral valve repair (n
3) or replacement (n  1), aortic valve replacement (n 
), and ventricular septal defect repair (n 1). Twenty-four
atients (62%) received isolated LVAD support and 15
atients (38%) received biventricular assist device (BVAD)
upport. In the IVAD study, a smaller percentage (38%) of
atients received BVADs, compared with 64% of patients in
he PVAD cohort (Table 2). For BTT, approximately half of
he patients in the IVAD cohort received BVADs, whereas
or postcardiotomy only 1 of 9 received a BVAD. Left
entricular apex cannulation was used in the IVAD study
or all LVADs, and right atrial (n  12) or right ventricular
n  2) cannulation was used for RVAD support. One day
fter VAD implantation, the mean LVAD pump flow index
as 2.5  0.5 L/(min · m2), significantly increased from a
ean preoperative cardiac index of 1.8 0.5 L/(min · m2).
t 60 days, resting LVAD flow index averaged 2.7  0.3
/(min · m2) (2.2-3.3 L/[min · m2]); pump flow averaged
.2  0.7 L/min (4.1-6.8 L/min). RVAD flow rates were
lightly lower, averaging 2.1  0.3 L/(min · m2) on the
rst postoperative day and remaining relatively stable
hereafter.
uration of Support
VAD support duration for the 39 patients was 3938 patient-
ays (10.8 patient-years), with an average support time of
01 days (Table 2). The mean duration of support for the 30
atients supported for BTT was 108 days (9–597 days), and
he mean duration for the postcardiotomy patients was 77
ays (14–250 days). Lengths of support have increased
ince the PVAD trial, when the average durations were 35
ays for BTT and 12 days for postcardiotomy recovery.
ighteen patients were discharged from the hospital with
he IVAD system for a mean duration of 96 days (2–454
ays). Forty-four percent of the total patient-days of support
ith the IVAD in the clinical trial were spent out of the
ospital. Ten patients required 15 hospital readmissions,
nd an additional patient had 12 readmissions, for reasons
ncluding arrhythmias, pleural effusion and right heart fail-
and Cardiovascular Surgery ● Volume 133, Number 6 1575
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1
CSPre, fever and dehydration, nose bleed, wound drainage, and
eurologic symptoms.
unctional Status
ll discharged patients engaged in light-to-moderate phys-
cal activity after discharge, including walking, shopping,
isiting family and friends, and entertainment. By week 8,
9% of the patients were in NYHA functional class I or II,
significant improvement from the 93% of patients in
YHA functional class IV before implantation. Average
ABLE 1. Baseline demographic, hemodynamic, and labo
aracorporeal ventricular assist device groups
arameter
emographics
Age (y) 48
Weight (kg) 77
Body surface area (m2) 1.91
Male/female ratio
Bridge to transplantation/postcardiotomy ratio
emodynamics
Cardiac index (L/[min · m2])
Left atrial pressure or pulmonary capillary
wedge pressure (mm Hg)
Right atrial pressure or central venous
pressure (mm Hg)
Mean arterial pressure (mm Hg)
Systolic blood pressure (mm Hg)
Mean pulmonary arterial pressure (mm Hg)
Venous oxygen saturation (%)
Heart rate (beats/min)
Left ventricular ejection fraction (%)
aboratory values*
Serum creatinine (mg/dL)
Blood urea nitrogen (mg/dL)
Alanine aminotransferase (U/L)
Aspartate aminotransferase (U/L)
Total bilirubin (mg/dL)
White blood cell count (103 cells/L)
Hematocrit (%)
alues are mean SD, with range given in parentheses as appropriate. IVA
evice; ND, not determined. *Bridge to transplantation only.
ABLE 2. Percentages of patients receiving left ventricula
ssist device and paracorporeal ventricular assist device
IVAD (n
BTT (n  30) PC (n
eft ventricular assist device (No.) 16 (53%) 8 (89
iventricular assist device (No.) 14 (47%) 1 (11
upport duration (d, mean and range) 108 (9-597) 77 (1VAD, Implantable ventricular assist device; PVAD, paracorporeal ventricular a
576 The Journal of Thoracic and Cardiovascular Surgery ● Junmprovement was 1.8 functional classes, from an average of
.9 at baseline to 2.1 at week 8.
urvival
wenty-seven of the 39 patients (69%) were successfully
upported to cardiac transplantation or device removal for
yocardial recovery (Table 3), an overall survival similar to
hat in the PVAD trial and significantly better than the 0%
urvival in the non-VAD medically managed control group
rom the original PVAD study.20 The postcardiotomy survival
ry values for implantable ventricular assist device and
IVAD PVAD P value
 39 n 100
4 (16-71) 46 12 (17-66) .302
5 (42-115) 76 18 (40-127) .906
.23 (1.31-2.40) 1.9 0.2 (1.3-2.6) .877
(72%:28%) 77:23 (77%:23%) .518
(77%:23%) 71:29 (71%:29%) .532
 39 n 100
.8  0.5 1.4  0.6 .002
.5 7.2 28.2  7.7 .272
.3 7.0 17.7  7.2 .361
9 14 61  12 .006
2 19 76  15 .0001
0 12 36  11 .187
 23% ND ND
8 17 ND ND
 7% 21%  15% .080
 30 n  69
.4 0.6 1.5  0.6 .448
.1 20.4 32.4  16.4 .487
3 541 ND
0 339 270 936 .568
.1 2.8 1.6  1.0 .207
.4  4.5 13.6 6.3 .001
 7.6% 33.2% 5.9% .624
plantable ventricular assist device; PVAD, paracorporeal ventricular assist
d biventricular assist devices for implantable ventricular
ps divided by indication
) PVAD (n  100)
Total BTT (n  71) PC (n  29) Total
24 (62%) 22 (35%) 14 (48%) 36 (36%)
15 (38%) 49 (69%) 15 (52%) 64 (64%)
) 101 (9-597) 35 (0-247) 12 (0-80) 28 (0-247)rato
n
 1
 1
 0
28:11
30:9
n
1
26
16
6
9
4
61%
9
16%
n
1
35
27
15
2
9
32.5%
D, Imr an
grou
 39
 9)
%)
%)
4-250ssist device; BTT, bridge to transplantation; PC, postcardiotomy.
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CS
P67%) was similar to that for BTT (70%). One patient (3.3%)
ecovered ventricular function in the BTT arm and was weaned
rom the VAD, and 2 (22%) patients in the postcardiotomy
rm received heart transplants, illustrating the challenge in
dentifying the ultimate patient outcome at the time of im-
lantation. When divided into univentricular or biventricu-
ar IVAD support for BTT (Table 3B), 13 of the 16 patients
eceiving LVAD support (81%) and 8 of the 14 patients
equiring BVAD support (57%) underwent transplantation
r weaning. Twenty-two (81%) of the 27 patients who either
nderwent transplantation or were weaned from the device
ere alive 30 days after VAD removal. For postcardiotomy
upport, 6 (75%) of the 8 patients with LVAD support were
eaned or underwent transplantation; the single patient with
VAD patient died. Twenty (91%) of the 22 patients who
nderwent cardiac transplantation were discharged alive
rom the hospital.
dverse Events
eventy-nine percent of the adverse events occurred within
0 days of implantation, with most occurring while the
atient was hospitalized. Adverse event rates for the IVAD
ere generally less than or comparable to those for the
VAD (Table 4). Infection accounted for most IVAD ad-
erse events, with 42 events in 22 patients. There were 5
atients with driveline infections and 2 with pump pocket
nfections. Thirty-four of the 42 events were local infec-
ABLE 3B. Bridge to transplantation outcomes for implan
ssist device groups requiring left ventricular and biventr
IVAD
LVAD BVAD
mplanted 16 14
urvived 13 (81.3%) 8 (57.1%) 2
Weaned 0 (0.0%) 1 (7.1%)
Transplanted 13 (81.3%) 7 (50.0%) 2
ied on device 3 (18.7%) 6 (42.9%)
VAD, Implantable ventricular assist device; PVAD, paracorporeal ventricul
evice.
ABLE 3A. Outcomes for implantable ventricular assist dev
y indication
IVAD
BTT PC
mplanted 30 9
urvived 21 (70.0%) 6 (66.7%) 2
Weaned 1 (3.3%) 4 (44.4%)
Transplanted 20 (66.7%) 2 (22.2%) 2
ied on device 9 (30.0%) 3 (33.3%) 1
VAD, Implantable ventricular assist device; PVAD, paracorporeal ventricuions, and the remaining 8 events were systemic. All infec- I
The Journal of Thoracicions were treated with antibiotics. Of the 18 patients (46%)
ith bleeding events, 42% occurred within 1 day of IVAD
mplantation. A single patient with severe hepatic dysfunction
ccounted for 28% of all bleeding events. Twenty-one neuro-
ogic events (including stroke, transient ischemic attack, en-
ephalopathy, and peripheral weakness) occurred in 14 pa-
ients, of which 57% (12/21) were transient ischemic attacks in
patients that resolved within 24 hours. Three patients had
oderate to severe stokes: 1 patient had occipital infarctions on
ays 18 and 24, and 2 patients had intracranial bleeding after
ays 53 and 87 that resulted in death. An additional patient fell
hile exercising, had a subdural hematoma develop, and
ied. The percentages of patients with ischemic or hemor-
hagic stroke were 7.7% (3/39) for the IVAD cohort and
2.0% (12/100) for the PVAD cohort. The percentages of
atients with transient ischemic attack were 20.5% (8/39)
or the IVAD cohort and 5.0% (5/100) for the PVAD
ohort. Reoperations were required in 54% (21/39) of the
VAD cohort and in 48% (48/100) of the PVAD cohort.
hirteen of these 21 patients with IVADs underwent explo-
ation for bleeding or for cardiac tamponade within the first
ew days. Five reoperations were required to correct IVAD
roblems (2 reoperations to improve the pump pocket in 1
atient, 1 reoperation to reposition the VAD to correct a
ink in the cannulas, 1 reoperation to replace the inflow
annula, and 1 reoperation to inspect the operation of the
ventricular assist device and paracorporeal ventricular
r assist devices
PVAD
al LVAD BVAD Total
71 29 100
.0%) 49 (69.0%) 14 (48.3%) 63 (63.0%)
%) 0 14 (48.3%) 14 (14.0%)
.7%) 49 (69.0%) 0 49 (49.0%)
.0%) 22 (31.0%) 15 (51.7%) 51 (51.0%)
ist device; LVAD, left ventricular assist device; BVAD, biventricular assist
nd paracorporeal ventricular assist device groups divided
PVAD
al BTT PC Total
71 29 100
.2%) 49 (69.0%) 14 (48.3%) 63 (63.0%)
.8%) 0 14 (48.3%) 14 (14.0%)
.4%) 49 (69.0%) 0 49 (49.0%)
.8%) 22 (31.0%) 15 (51.7%) 51 (51.0%)
ssist device; BTT, bridge to transplantation; PC, postcardiotomy.table
icula
Tot
30
1 (70
1 (3.3
0 (66
9 (30
ar assice a
Tot
39
7 (69
5 (12
2 (56
2 (30VAD inflow valve). One patient with LVAD support re-
and Cardiovascular Surgery ● Volume 133, Number 6 1577
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1
CSPeived a paracorporeal RVAD on postoperative day 16 and
nderwent transplantation 63 days later. This patient was
ncluded in the analysis as receiving a BVAD.
Renal dysfunction occurred in 10 patients (26%), and
epatic dysfunction occurred in 14 patients (36%). Renal
nd hepatic function improved during IVAD support, as
videnced by changes in creatinine, blood urea nitrogen,
nd alanine aminotransferase. Patients who required
VADs had higher preoperative values than did patients
ho required only LVAD support, and their values re-
ained elevated longer before improving to the normal
ange.
There were no serious IVAD failures, and no IVADs
equired replacement. There were 10 pump or cable mal-
unctions related to the loss of pump full or empty signals
rom the device. Patients with loss of the full signal had the
ystem managed in fixed rate mode rather than automatic rate
ode without consequence. There were 10 patients with bat-
ery, charger, or driver malfunctions, including excess noise
r nuisance alarms. One driveline was noted to be broken
uring explantation, and 2 instances of kinked cannulas
ere reported.
There were 2 perioperative deaths (9%) after transplan-
ation, 1 from right ventricular failure and pulmonary edema
nd 1 from multiorgan failure. Two patients weaned from
VAD support after postcardiotomy ventricular failure died
efore discharge from gangrenous bowel or multiple organ
ailure. Twelve patients died while supported by the device,
from multiple organ failure in the first 2 to 5 weeks, 2
rom hemorrhagic cerebrovascular accident, 2 from sepsis,
nd 1 from a subdural hematoma after a fall while at home.
iscussion
he results from this clinical trial demonstrate that the
VAD, an implantable version of the Thoratec PVAD sys-
ABLE 4. Adverse event rates for implantable ventricular as
IVAD (n  39)
umulative patient-days of support 3938
nfection 0.32
leeding 0.27
eurologic dysfunction 0.16
epatic dysfunction 0.11
rrhythmias 0.09
espiratory failure 0.09
leural effusion 0.09
enal failure 0.08
ardiac tamponade 0.07
emolysis 0.02
eripheral thromboembolism 0.02
ight heart failure 0.01
ates are events per 30 patient-days.em, has comparable survival and reduced complication d
578 The Journal of Thoracic and Cardiovascular Surgery ● Junates relative to the PVAD and provides an additional option
or patients with advanced heart failure who required sup-
ort as a BTT or pending recovery of the native heart. All
atients received sufficient blood flow to restore hemody-
amic values. Major organ function improved, and stable
ulsatile circulatory support was provided by the IVAD for
s long as 18 months. There were significant improvements
n patient functional status, with more than two thirds of
atients in NYHA functional class I or II by the 8th week of
upport. Patients were successfully discharged from the
ospital and were active until transplantation or cardiac
ecovery. This is the first successful clinical trial of an
mplantable circulatory support system providing biven-
ricular assistance.
In this study, 70% of the combined LVAD and BVAD
ubgroups of patients treated with the IVAD for BTT had
uccessful weaning or transplantation, an outcome similar to
hose reported in other multicenter BTT clinical trials, includ-
ng those of the Thoratec PVAD (69%),20 the HeartMate IP
VAD (71%),6 the HeartMate VE Left Ventricular Assist
ystem (LVAS, 71%),10 the Novacor LVAS (78%),11 and
he Cardiowest Total Artificial Heart (79%).13 Patients who
eceived the IVAD for isolated left ventricular support had
n 81% survival to cardiac transplantation. Patients who
equired biventricular support had lower survival (57%),
onsistent with previous studies demonstrating that patients
ith increased severity of illness, especially with renal and
epatic failure, are more likely to require BVADs and thus
e at higher risk for death than patients supported with
solated LVADs.7,21,24 In previous studies, one center re-
orted using Thoratec BVADs for all of their patients with
ood results,22 whereas other single centers with more than
00 implants with the Thoratec VAD have reported 30% to
0% of patients treated as BTT receiving BVADs.8,23,24
hese percentages, with patients selected because of the
device and paracorporeal ventricular assist device groups
PVAD (n  100) Risk ratio (95% confidence interval)
2857
0.61 0.53 (0.35-0.78)
0.66 0.41 (0.27-0.63)
0.43 0.37 (0.22-0.63)
0.69 0.16 (0.09-0.29)
0.23 0.40 (0.20-0.80)
0.15 0.62 (0.29-1.35)
0.11 0.87 (0.38-2.02)
0.21 0.36 (0.17-0.78)
0.05 1.31 (0.44-3.90)
0.07 0.21 (0.04-1.00)
0.16 0.10 (0.02-0.42)
0.09 0.08 (0.01-0.64)sistevice’s biventricular capability, are typically higher than
e 2007
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CS
Phe 7% to 15% incidence of RVAD use in the clinical
xperience of implantable electric LVADs,9-12 with patients
elected with the goal of univentricular support. Improved
atient selection and earlier implantation remain the key
actors that could reduce the 25% to 35% mortality among
atients who do not survive to transplantation with the use
f any VAD.
All adverse events reported in the trial were anticipated,
nd most occurred within the first 30 days after implanta-
ion. This is consistent with findings reported in the previous
horatec PVAD and HeartMate LVAS studies. Only 1
atient had an embolic stroke and 2 had hemorrhagic
trokes during IVAD support, and there were no device
ailures. Infection remains a concern for patients receiving
ny LVAD system and accounted for most adverse events;
evice-related infections were limited in the IVAD study to
pocket infections and 5 driveline infections, however, and
epsis was reported as the cause of death in only 2 cases.
One recognized limitation of the IVAD study was that it
sed a historical control group from the original clinical trial
f the PVAD for comparisons of outcomes and adverse
vents. Clearly, patient management has changed since that
tudy was conducted more than a decade ago, which could
ave an effect on detailed comparisons between these groups.
he PVAD cohort is a suitable comparison group, however, in
hat the design and intended use of the PVAD and IVAD are
imilar, both pumps use the same pneumatic power sources,
nd both trials used similar inclusion and exclusion criteria
o enroll patients. Thus no concurrent control group was
eemed necessary to establish the basic equivalence of the
VAD with the PVAD.
The selection process regarding which device is best
uited for a given patient and when the IVAD would be the
ppropriate choice is becoming more complex, especially
ith the emergence of the newer continuous-flow LVADs,
hich also address the need for smaller devices. For those
rograms that are not able to keep multiple devices on the
helf or for centers with existing experience with the PVAD,
he IVAD seems like a logical choice because of its versa-
ility and use for both BTT and postcardiotomy shock. The
VAD would also be an appropriate option for patients with
high likelihood of needing biventricular support.
The principal need for an option for implantation of the
horatec IVAD is to facilitate hospital discharge, improve
ostoperative management, and help patients with psycho-
ocial issues and acceptance of the device. Although patients
ith PVADs can be and are now being discharged from the
ospital,25 in many cases implantation may be preferable for
ong-term support and for outpatient management. Paracorpo-
eal placement is preferable for short-term support, for ex-
mple for less than 30 days, and for smaller patients26 and
hose with other anatomic placement issues. Although im-
lantable rotary pumps are showing much promise as small
The Journal of Thoracicnd quiet alternatives to the large first-generation electric
VADs, the IVAD is the smallest and lightest pulsatile
AD and has less motion and a smaller driveline than the
urrently available electric pulsatile LVADs. On the other
and, electric LVADs have the advantage of wearability and
ay be preferable for large patients who need long-term
upport, so long as it is known that only left ventricular
upport will be required. It is generally believed that smaller
evices with less motion and smaller, more flexible driv-
lines will result in fewer infections and greater ease of
utpatient management. Although these long sought after
linical benefits from smaller devices were not clearly dem-
nstrated in this initial pilot study, it is to be hoped that they
ill be seen with increased use and continued improve-
ents in patient management.
The Thoratec IVAD has demonstrated the capability of
roviding univentricular and biventricular support in a wide
ange of patients with a body surface area as small as 1.3
2
. Long-term cardiac support was provided for as long as
97 days, and patients were successfully discharged from
he hospital to await cardiac transplantation or myocardial
ecovery. The IVAD operated reliably, and there were no
eported device failures. The results of this study establish
he Thoratec IVAD as a viable option for patients with
nd-stage heart failure.
The coauthors acknowledge the other IVAD Study Group
embers: Nelson A. Burton, MD, Inova Fairfax Hospital, Annan-
ale, Va; Kathy Magliato, MD, Cedars Sinai Medical Center, Los
ngeles, Calif; James C. Spann, MD, St Francis Hospital, Tulsa,
kla; Olivier Bastien, MD, PhD, Hospices Civils de Lyon, Lyon,
rance; and Jack Copeland, MD, University of Arizona, Tucson,
riz.
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o be enrolled, the patient had to meet criteria 1 and 2 and either
or 4:
1. The patient has body surface area greater than 1.3 m2.
2. The patient remains in cardiac failure despite appropriate
use of conventional therapies such as inotropic agents,
vasodilators, or intra-aortic balloon pump, as documented
by the following:
a. Pulmonary capillary wedge pressure greater than 20 mm
Hg and eitherb. Cardiac index less than 2.0 L/(min m2) or
The Journal of Thoracic anc. Mixed venous oxygen saturation less than 50% or
d. Systolic arterial pressure less than 90 mm Hg, or mean
arterial pressure less than 70 mm Hg.
3. The patient requires ventricular assist device support as
bridge to transplantation and meets the following criteria:
a. Fulfills cardiac transplantation requirements for the center
and
b. Has imminent risk of dying before donor heart procurement.
4. The postcardiotomy patient is unable to be weaned from
cardiopulmonary bypass and requires ventricular assist de-
vice support pending myocardial recovery.
d Cardiovascular Surgery ● Volume 133, Number 6 1580.e1
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1
CSPFigure E1. Implantable ventricular assist device is placed in preperitoneal position and is small enough to be used
for univentricular (A) or biventricular (B) support. One percutaneous pneumatic driveline is tunneled for each
ventricular assist device.580.e2 The Journal of Thoracic and Cardiovascular Surgery ● June 2007
